Daniel Peisert Email & Phone Number

Chicago, IL, US

Established new strategic vision and repositioned Company with a new commercial model to create a sustainable competitive advantage. Returned the business to profitability. Transformed the balance sheet. Completed two product acquisitions and a corporate merger to diversify the business and add patent protected growth drivers.

Led turnaround and transformation of the Company through multiple divestitures, out licensing partnerships and accelerated debt retirement. Architect of the new co Holding Company structure designed to segregate assets from liabilities (opioid & shareholder litigation) which facilitated the merger with Zyla.

Full P&L responsibility for $140 million EBITDA business unit. Developed and executed the action plan to stabilize the business and return it to growth.

Executed strategic M&A plans including sourcing, evaluation, negotiation and commercial & financial diligence for all acquisitions. Completed $4.9 Billion of acquisitions and related debt and equity financing.

Responsible for analysis, stock selection and position sizing primarily within healthcare sector for $1.5 Billion AUM long only thematic, growth portfolio

Responsible for Finance, Business Development and several operational duties for a private equity backed start-up pharmaceutical company focused of growth via acquisition. Established all financial infrastructure and controls at company inception.

Senior Healthcare Analyst for the small cap portfolio

Focused on investments in healthcare in three roles at UBS O'Connor: Analyst & Co-PM for a long/short market neutral mid cap portfolio; Portfolio Manager of a $85M long/short market neutral portfolio of Specialty Pharmaceuticals stocks; Junior Analyst for the $1 Billion long/short Healthcare portfolio (Large Cap Pharma, Large Cap Med Tech & Biotech)

Investment pricing, P&L calculations and financial reporting for the UBS proprietary trading portfolios (Convert Arb, Risk Arb, Fundamental Long Short Equity, Equity Option)